ビグアナイドの世界市場レポート 2024年

ビグアナイドの市場規模は、今後数年間で安定した成長が見込まれます。2028年の年間平均成長率（CAGR）は3.8％で、57億6,000万米ドルに成長します。予測期間中に予想される成長は、併用療法の採用増加、ドラッグデリバリー技術の進歩、研究開発投資の増加、ヘルスケア支出の拡大、多嚢胞性卵巣症候群治療への応用拡大などの要因によって促進されると予想されます。この期間に予測される重要な動向には、徐放性製剤の開発への注目の高まり、合剤治療への嗜好の高まり、がん領域での用途の拡大、有効性と安全性のプロファイルを改善した新規ビグアナイドの出現などがあります。

糖尿病患者の増加は、当面ビグアナイド市場の拡大を牽引すると予想されます。糖尿病は、インスリン分泌不足による血糖値の上昇を特徴とする慢性代謝疾患であり、ライフスタイルの変化、人口の高齢化、遺伝的要因、診断方法の改善、環境の影響など様々な要因によって増加傾向にあります。メトホルミンなどのビグアナイドは、インスリン感受性を高め、肝臓でのグルコース産生を抑え、2型糖尿病患者の血糖値を下げることで、糖尿病の管理に役立ちます。例えば、英国の政府機関であるOffice for Health Improvement &Disparitiesによると、2022年3月から2023年3月にかけて、1型糖尿病と2型糖尿病に対して推奨される8つのケアプロセスをすべて受けている人の割合が大幅に増加しました。さらに、HbA1cの目標値を達成した人の割合は過去最高の37.9％に達しました。したがって、糖尿病有病率の増加がビグアナイド市場の成長を促進しています。

ビグアナイド市場の大手企業は、患者のコンプライアンスを高め、治療効果を改善し、副作用を最小限に抑えるために、徐放性製剤などの先進的なソリューションの開発に注力しています。徐放性ビグアナイドは有効成分をゆっくりと放出するため、糖尿病患者の血中濃度を一定に保ち、血糖コントロールを改善し、治療のアドヒアランスを高める。例えば、2023年8月、インドのバイオテクノロジー企業であるDr. Reddy's Laboratories社は、米国食品医薬品局（USFDA）から承認されたKOMBIGLYZE XRのジェネリック医薬品であるサキサグリプチンおよび塩酸メトホルミン徐放性製剤を発売しました。本剤は、DPP-4阻害剤であるサキサグリプチンとビグアナイド系薬剤であるメトホルミンの配合剤で、食事療法や運動療法と併用することにより、成人の2型糖尿病患者の血糖コントロールを改善することを目的としています。徐放性製剤は、患者の服薬アドヒアランスと有効性を高める。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界の市場規模と成長

• 世界のビグアナイド市場：促進要因と抑制要因
  • 市場促進要因
  • 市場抑制要因
• 世界のビグアナイド市場の実績：規模と成長, 2018-2023
• 世界のビグアナイド市場の予測：規模と成長, 2023-2028, 2033F

第6章 市場セグメンテーション

• 世界のビグアナイド市場：タイプ別、実績と予測, 2018-2023, 2023-2028F, 2033F
• メトホルミン
• フェンホルミン
• その他のタイプ
• 世界のビグアナイド市場：剤形別、実績と予測, 2018-2023, 2023-2028F, 2033F
• タブレット
• 経口ソリューション
• 世界のビグアナイド市場：製剤別、実績と予測, 2018-2023, 2023-2028F, 2033F
• 即時リリース
• 延長リリース
• 世界のビグアナイド市場：流通チャネル別、実績と予測, 2018-2023, 2023-2028F, 2033F
• 病院薬局
• 小売薬局
• オンライン薬局

第7章 地域別・国別分析

• 世界のビグアナイド市場：地域別、実績と予測, 2018-2023, 2023-2028F, 2033F
• 世界のビグアナイド市場：国別、実績と予測, 2018-2023, 2023-2028F, 2033F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• ビグアナイド市場：競合情勢
• ビグアナイド市場：企業プロファイル
  • Cardinal Health Inc.
  • Pfizer Inc.
  • Merck And Co Inc
  • Bayer AG
  • Sanofi-Aventis LLC

第31章 その他の大手企業と革新的企業

• AstraZeneca plc
• Novartis AG
• GlaxoSmithKline plc
• Takeda Pharmaceuticals Company Limited
• Novo Nordisk A/S
• Viatris Inc.
• Daiichi Sankyo Company Limited
• Wanbury Ltd
• Boehringer Ingelheim International GmbH
• Intas Pharmaceuticals Ltd.
• Aurobindo Pharma Ltd.
• Cipla Ltd
• Shionogi & Co Ltd
• Dr. Reddy's Laboratories
• Lupin Limited

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと潜在的な分析

第36章 付録

Biguanides comprise a class of medications primarily employed in the treatment of type 2 diabetes. They aid in lowering blood sugar levels by reducing the liver's production of sugar and enhancing the body's responsiveness to insulin. Additionally, these medications find utility in treating polycystic ovary syndrome (PCOS) and other metabolic disorders.

The primary types of biguanides include metformin, phenformin, and others. Metformin stands out as a widely utilized biguanide medication for type 2 diabetes management, effectively lowering blood sugar levels. Available in various dosage forms such as tablets and oral solutions, metformin is offered in different formulations including immediate-release and extended-release variants. These medications are distributed through a variety of channels including hospital pharmacies, retail pharmacies, and online platforms.

The biguanides market research report is one of a series of new reports from The Business Research Company that provides biguanides market statistics, including biguanides industry global market size, regional shares, competitors with a biguanides market share, detailed biguanides market segments, market trends and opportunities, and any further data you may need to thrive in the biguanides industry. This biguanides market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The biguanides market size has grown steadily in recent years. It will grow from $4.79 billion in 2023 to $4.96 billion in 2024 at a compound annual growth rate (CAGR) of 3.6%. The growth observed in the historical period can be attributed to several factors, including an increase in demand for oral hypoglycemic drugs, the growth of the geriatric population, rising obesity rates, and heightened awareness about diabetes management.

The biguanides market size is expected to see steady growth in the next few years. It will grow to $5.76 billion in 2028 at a compound annual growth rate (CAGR) of 3.8%. The anticipated growth in the forecast period is expected to be fueled by factors such as the increasing adoption of combination therapies, advancements in drug delivery technologies, rising investment in research and development, expanding healthcare expenditure, and broadening applications in the treatment of polycystic ovary syndrome. Significant trends projected for this period include a heightened focus on developing extended-release formulations, a growing preference for fixed-dose combination therapies, expanding applications in oncology, and the emergence of novel biguanides with improved efficacy and safety profiles.

The increase in diabetes cases is anticipated to drive the expansion of the biguanides market in the foreseeable future. Diabetes, a chronic metabolic disorder characterized by elevated blood sugar levels due to insufficient insulin production, is on the rise due to various factors such as lifestyle shifts, population aging, genetic factors, improved diagnostic methods, and environmental influences. Biguanides such as metformin help manage diabetes by enhancing insulin sensitivity, reducing liver glucose production, and lowering blood sugar levels in individuals with type 2 diabetes. For example, according to the Office for Health Improvement & Disparities, a UK-based government department, between March 2022 and March 2023, the percentage of individuals receiving all eight recommended care processes for type 1 and type 2 diabetes increased significantly. Additionally, the percentage of individuals achieving target HbA1c levels reached a record high of 37.9%. Therefore, the increasing prevalence of diabetes is propelling the growth of the biguanides market.

Leading companies in the biguanides market are concentrating on developing advanced solutions such as extended-release formulations to enhance patient compliance, improve therapeutic effectiveness, and minimize side effects. Extended-release biguanides slowly release their active ingredients, ensuring consistent blood levels and better glycemic control for diabetes patients, thereby enhancing treatment adherence. For instance, in August 2023, Dr. Reddy's Laboratories, an India-based biotechnology company, introduced saxagliptin and metformin hydrochloride extended-release drugs, a generic version of KOMBIGLYZE XR approved by the US Food and Drug Administration (USFDA). This combination medication, consisting of saxagliptin, a DPP-4 inhibitor, and metformin, a biguanide, aims to improve glycemic control in adults with type 2 diabetes mellitus when used in conjunction with diet and exercise. The extended-release formulation enhances patient adherence and efficacy.

In August 2023, Lupin, an India-based biopharmaceutical company, acquired diabetes brands ONDERO and ONDERO MET from Boehringer Ingelheim for an undisclosed sum. This acquisition enables Lupin to expand its product portfolio and strengthen its position in the anti-diabetes segment, ensuring broader access to medication for patients. Boehringer Ingelheim, a Germany-based biopharmaceutical company, is renowned for its research, development, and production of therapies for both human and veterinary medicine.

Major companies operating in the biguanides market are Cardinal Health Inc., Pfizer Inc., Merck And Co Inc, Bayer AG, Sanofi-Aventis LLC, AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceuticals Company Limited, Novo Nordisk A/S, Viatris Inc., Daiichi Sankyo Company Limited, Wanbury Ltd, Boehringer Ingelheim International GmbH, Intas Pharmaceuticals Ltd., Aurobindo Pharma Ltd., Cipla Ltd, Shionogi & Co Ltd, Dr. Reddy's Laboratories, Lupin Limited, Zydus Lifesciences Limited, Apotex Inc, Torrent Pharmaceuticals Limited, Panacea Biotech Ltd., Auro Laboratories Limited

Asia-Pacific was the largest region in the biguanides market in 2023. Middle East And Africa is expected to be the fastest-growing region in the forecast period. The regions covered in the biguanides market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the biguanides market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The biguanides market consists of sales of Chlorhexidine, Polyhexanide, Proguanil, and Buformin. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Biguanides Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on biguanides market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for biguanides ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The biguanides market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of COVID-19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Metformin; Phenformin; Other Types
• 2) By Dosage Form: Tablets; Oral Solutions
• 3) By Formulation: Immediate Release; Extended Release
• 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• Companies Mentioned: Cardinal Health Inc.; Pfizer Inc.; Merck And Co Inc; Bayer AG; Sanofi-Aventis LLC
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Biguanides Market Characteristics

3. Biguanides Market Trends And Strategies

4. Biguanides Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On The Market
• 4.2. Ukraine-Russia War Impact On The Market
• 4.3. COVID-19 Impact On The Market

5. Global Biguanides Market Size and Growth

• 5.1. Global Biguanides Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Biguanides Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Biguanides Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Biguanides Market Segmentation

• 6.1. Global Biguanides Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Metformin
• Phenformin
• Other Types
• 6.2. Global Biguanides Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Tablets
• Oral Solutions
• 6.3. Global Biguanides Market, Segmentation By Formulation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Immediate Release
• Extended Release
• 6.4. Global Biguanides Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

7. Biguanides Market Regional And Country Analysis

• 7.1. Global Biguanides Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Biguanides Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Biguanides Market

• 8.1. Asia-Pacific Biguanides Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Biguanides Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Biguanides Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Biguanides Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Biguanides Market

• 9.1. China Biguanides Market Overview
• 9.2. China Biguanides Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Biguanides Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Biguanides Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Biguanides Market

• 10.1. India Biguanides Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Biguanides Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Biguanides Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Biguanides Market

• 11.1. Japan Biguanides Market Overview
• 11.2. Japan Biguanides Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Biguanides Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Biguanides Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Biguanides Market

• 12.1. Australia Biguanides Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Biguanides Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Biguanides Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Biguanides Market

• 13.1. Indonesia Biguanides Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Biguanides Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Biguanides Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Biguanides Market

• 14.1. South Korea Biguanides Market Overview
• 14.2. South Korea Biguanides Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Biguanides Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Biguanides Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Biguanides Market

• 15.1. Western Europe Biguanides Market Overview
• 15.2. Western Europe Biguanides Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Biguanides Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Biguanides Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Biguanides Market

• 16.1. UK Biguanides Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Biguanides Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Biguanides Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Biguanides Market

• 17.1. Germany Biguanides Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Biguanides Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Biguanides Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Biguanides Market

• 18.1. France Biguanides Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Biguanides Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Biguanides Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Biguanides Market

• 19.1. Italy Biguanides Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Biguanides Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Biguanides Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Biguanides Market

• 20.1. Spain Biguanides Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Biguanides Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain Biguanides Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Biguanides Market

• 21.1. Eastern Europe Biguanides Market Overview
• 21.2. Eastern Europe Biguanides Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Biguanides Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Biguanides Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Biguanides Market

• 22.1. Russia Biguanides Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Biguanides Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Biguanides Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Biguanides Market

• 23.1. North America Biguanides Market Overview
• 23.2. North America Biguanides Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Biguanides Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Biguanides Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Biguanides Market

• 24.1. USA Biguanides Market Overview
• 24.2. USA Biguanides Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Biguanides Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Biguanides Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Biguanides Market

• 25.1. Canada Biguanides Market Overview
• 25.2. Canada Biguanides Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Biguanides Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Biguanides Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Biguanides Market

• 26.1. South America Biguanides Market Overview
• 26.2. South America Biguanides Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Biguanides Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Biguanides Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Biguanides Market

• 27.1. Brazil Biguanides Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Biguanides Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Biguanides Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Biguanides Market

• 28.1. Middle East Biguanides Market Overview
• 28.2. Middle East Biguanides Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Biguanides Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Biguanides Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Biguanides Market

• 29.1. Africa Biguanides Market Overview
• 29.2. Africa Biguanides Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Biguanides Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Biguanides Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Biguanides Market Competitive Landscape And Company Profiles

• 30.1. Biguanides Market Competitive Landscape
• 30.2. Biguanides Market Company Profiles
  • 30.2.1. Cardinal Health Inc.
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. Pfizer Inc.
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. Merck And Co Inc
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. Bayer AG
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. Sanofi-Aventis LLC
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Biguanides Market Other Major And Innovative Companies

• 31.1. AstraZeneca plc
• 31.2. Novartis AG
• 31.3. GlaxoSmithKline plc
• 31.4. Takeda Pharmaceuticals Company Limited
• 31.5. Novo Nordisk A/S
• 31.6. Viatris Inc.
• 31.7. Daiichi Sankyo Company Limited
• 31.8. Wanbury Ltd
• 31.9. Boehringer Ingelheim International GmbH
• 31.10. Intas Pharmaceuticals Ltd.
• 31.11. Aurobindo Pharma Ltd.
• 31.12. Cipla Ltd
• 31.13. Shionogi & Co Ltd
• 31.14. Dr. Reddy's Laboratories
• 31.15. Lupin Limited

32. Global Biguanides Market Competitive Benchmarking

33. Global Biguanides Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Biguanides Market

35. Biguanides Market Future Outlook and Potential Analysis

• 35.1 Biguanides Market In 2028 - Countries Offering Most New Opportunities
• 35.2 Biguanides Market In 2028 - Segments Offering Most New Opportunities
• 35.3 Biguanides Market In 2028 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer